DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, will be prominently featured at the upcoming Cantor Global Healthcare Conference. The conference, taking place in New York City from September 3rd to 5th, 2025, will host Rick Pauls, President and CEO, and Dave Wambeke, Chief Business Officer, for a presentation.
The presentation, a fireside chat, is scheduled for Thursday, September 4th, between 9:10 am and 9:40 am ET at the New York Marriott Marquis. Joshua Schimmer, Managing Director and Biotech Equity Research Analyst at Cantor Fitzgerald, will moderate the discussion. A live webcast will also be available.
Beyond the scheduled presentation, DiaMedica‘s leadership team will be available to meet with investors individually throughout the conference. These meetings will provide further opportunities for discussion and engagement.
DiaMedica is focused on developing innovative treatments for a range of serious ischemic diseases. These include preeclampsia, fetal growth restriction, and acute ischemic stroke. The company’s primary focus is on DM199, a novel treatment option.
DM199 is a recombinant form of the KLK1 protein, a substance already used in some parts of Asia to treat various vascular diseases. DiaMedica believes that DM199 holds significant potential as a therapeutic agent in the United States and other global markets. The company is actively pursuing clinical development for its lead candidate.
Interested parties can access the live webcast of the fireside chat via a link provided by DiaMedica. Investors seeking further information or to schedule individual meetings can contact the designated investor relations representatives. Media inquiries should be directed to the company’s media relations contact.
Related
